Onset of immunity in kittens after vaccination with a non-adjuvanted vaccine against feline panleucopenia, feline calicivirus and feline herpesvirus.
The induction of a quick onset of immunity against feline parvovirus (FPV), feline herpesvirus (FHV) and feline calicivirus (FCV) is critical both in young kittens after the decline of maternal antibodies and in cats at high risk of exposure. The onset of immunity for the core components was evaluated in 8-9 week old specific pathogen free kittens by challenge 1 week after vaccination with a combined modified live (FPV, FHV) and inactivated (FCV) vaccine. The protection obtained 1 week after vaccination was compared to that obtained when the challenge was performed 3-4 weeks after vaccination. The protocol consisted of a single injection for vaccination against FPV and two injections 4 weeks apart for FHV and FCV. At 1 week after vaccination, the kittens showed no FPV-induced clinical signs or leukopenia following challenge, and after FCV and FHV challenges the clinical score was significantly lower in vaccinated animals than in controls. Interestingly, the relative efficacy of the vaccination was comparable whether the animals were challenged 1 week or 3-4 weeks after vaccination, indicating that the onset of protection occurred within 7 days of vaccination. Following the 1-week challenge, excretion of FPV, FHV and FCV was significantly reduced in vaccinated cats compared to control kittens, confirming the onset of immunity within 7 days of vaccination.
Jas
D
D
Research and Development, Merial SAS, 29 Avenue Tony Garnier, 69007 Lyon, France.
Aeberlé
C
C
Lacombe
V
V
Guiot
A L
AL
Poulet
H
H
D000818:Animals; D000831:Animals, Newborn; D017250:Caliciviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D017927:Calicivirus, Feline / Q000276:immunology; D002371:Cat Diseases / Q000276:immunology / Q000517:prevention & control*; D002415:Cats; D005254:Feline Panleukopenia / Q000276:immunology / Q000517:prevention & control*; D028301:Feline Panleukopenia Virus / Q000276:immunology; D005260:Female; D006564:Herpesviridae / Q000276:immunology; D006566:Herpesviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D008297:Male; D013047:Specific Pathogen-Free Organisms; D014613:Vaccines, Attenuated; D017778:Vaccines, Combined; D015164:Vaccines, Inactivated; D014765:Viral Vaccines / Q000276:immunology*
D014613:Vaccines, Attenuated; D017778:Vaccines, Combined; D015164:Vaccines, Inactivated; D014765:Viral Vaccines